<DOC>
	<DOC>NCT01468350</DOC>
	<brief_summary>A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function</brief_summary>
	<brief_title>Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>A diagnosis of CP No previous use of any dalfampridine formulation Ability to perform all the required study procedures. Subjects should be capable of fully extending and flexing both hands Presence of any progressive neurological disease Severe CP defined as the requirement to use a wheelchair at all times and a care taker for constant assistance in daily activities. This definition includes spastic quadriplegia Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>